Clinical Trial

Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
ACM-CpG is a CpG-B TLR9 agonist, which in animal models has led to shrinkage and complete disappearance of injected tumors, durable antitumor memory, and growth inhibitory effects on non-injected tumors while intramuscular administration led to durable control of tumors. This Phase I trial will assess the safety and early signs of efficacy of intramuscular injection of ACM-CpG in patients with advanced malignant solid tumors. The overall objectives of this trial are to establish the safety ACM-CpG.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-05; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-03-18
Trial Details
NCT Number NCT06587295
Lead Sponsor National Cancer Centre, Singapore
Collaborators: ACM Biolabs
Conditions Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 40 participants
Start Date 2025-01-15
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-15